

A multi centre randomised controlled trial comparing intra operative cell salvage with standard care in the treatment of hip fractures

Submission date 27/08/2019	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 10/09/2019	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 09/06/2022	Condition category Injury, Occupational Diseases, Poisoning	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Current plain English summary as of 08/04/2020:

Background and study aims

Patients admitted with a hip fracture are typically elderly, frail and have multiple medical co-morbidities, including low red blood cell count (anaemia). As a consequence of the fracture and urgent surgery, patients sustain blood loss, worsening this pre-existing anaemia. In patients with a fractured hip allogenic (blood from a donor) blood transfusion is required in up to 30% of patients. Blood transfusions impose some risks to patients, such as an increased rate of infection. Allogenic blood use is associated with transfusion reactions and an increased length of hospital stay. Concerns regarding patient safety and the costs of allogenic blood have driven efforts to reduce transfusion rates. 'Intraoperative cell salvage and autotransfusion' is a method of collecting blood lost during surgery and transfusing it back to the patient. The cell salvage device separates oxygen-carrying red blood cells lost during surgery, prior to transfusing them back to the patient. Complications as a result of cell salvage are rare. Despite not currently being used routinely, there are large potential benefits of using cell salvage during hip fracture surgery. The study aim is to evaluate the clinical effectiveness of cell salvage in hip fracture surgery.

Who can participate?

Participants of 60 years of age and older who have sustained a fracture of the hip who, in the opinion of the operating surgeon, would benefit from surgery

What does the study involve?

The study will include a comparison between 'cell salvage' with 'treatment as usual' to the blood lost during hip surgery. Treatment as usual involves a standard suction system removing blood lost in the operation and disposed of in clinical waste. In either treatment arm patients may receive donor's blood transfusion before the operation. Then need for allogenic blood products will be determined on an individual patient basis, following each centres blood transfusion policy.

What are the possible benefits and risks of participating?

Any operation for a broken hip carries some risks. The risk of surgery with an implant include: bleeding requiring blood transfusion, infection, further fracture, dislocation, leg length discrepancy, blood clots, damage to nerves and blood vessels in the surgical care, and the risks associated with the anaesthetic. Allogenic blood transfusion carries the risk of increased rate of local and systematic infections. These risks are the same as for patients who are not part of this research project. Cell salvage is very safe as patients own blood is used. There is no specific advantage for participant taking part in the trials. However, the information we get from this trial will inform the future practice and will benefit future patients.

Where is the study run from?

John Radcliffe Hospital, Oxford, UK

When is the study starting and how long is it expected to run for?

October 2019 to March 2023

Who is funding the study?

National Institute for Health Research (NIHR)

Who is the main contact?

Katy Mironov

White9@ndorms.ox.ac.uk

Previous plain English summary:

Background and study aims

Patients admitted with a hip fracture are typically elderly, frail and have multiple medical co-morbidities, including low red blood cell count (anaemia). As a consequence of the fracture and urgent surgery, patients sustain blood loss, worsening this pre-existing anaemia. In patients with a fractured hip allogenic (blood from a donor) blood transfusion is required in up to 30% of patients. Blood transfusions impose some risks to patients, such as an increased rate of infection. Allogenic blood use is associated with transfusion reactions and an increased length of hospital stay. Concerns regarding patient safety and the costs of allogenic blood have driven efforts to reduce transfusion rates. 'Intraoperative cell salvage and autotransfusion' is a method of collecting blood lost during surgery and transfusing it back to the patient. The cell salvage device separates oxygen-carrying red blood cells lost during surgery, prior to transfusing them back to the patient. Complications as a result of cell salvage are rare. Despite not currently being used routinely, there are large potential benefits of using cell salvage during hip fracture surgery.

The study aim is to evaluate the clinical effectiveness of cell salvage in hip fracture surgery. Prior to assessing this in a full-size clinical trial we need to understand if surgeons and patients are willing to participate in such a study and if sufficient blood is lost during surgery to make cell salvage viable. Therefore this is a feasibility study to determine if a full study is possible and worthwhile.

Who can participate?

Participants of 60 years of age and older who have sustained a fracture of the hip who, in the opinion of the operating surgeon, would benefit from surgery

What does the study involve?

The study will include a comparison between 'cell salvage and autotransfusion' with 'treatment as usual' to the blood lost during hip surgery. Treatment as usual involves a standard suction

system removing blood lost in the operation and disposed of in clinical waste. In either treatment arm patients may receive donor's blood transfusion before the operation. Then need for allogenic blood products will be determined on an individual patient basis, following each centres blood transfusion policy.

What are the possible benefits and risks of participating?

Any operation for a broken hip carries some risks. The risk of surgery with an implant include: bleeding requiring blood transfusion, infection, further fracture, dislocation, leg length discrepancy, blood clots, damage to nerves and blood vessels in the surgical care, and the risks associated with the anaesthetic. Allogenic blood transfusion carries the risk of increased rate of local and systematic infections. These risks are the same as for patients who are not part of this research project. Cell salvage is very safe as patients own blood is used. There is no specific advantage for participant taking part in the trials. However, the information we get from this trial will inform the future practice and will benefit future patients.

Where is the study run from?

John Radcliffe Hospital, Oxford, UK

When is the study starting and how long is it expected to run for?

October 2019 to September 2020

Who is funding the study?

National Institute for Health Research (NIHR)

Who is the main contact?

Katy Mironov

White9@ndorms.ox.ac.uk

Study website

<https://white9.oxtru.ox.ac.uk/>

Contact information

Type(s)

Scientific

Contact name

Mrs Katy Mironov

Contact details

Oxford Trauma Kadoorie Centre Level 3

John Radcliffe Hospital

Headley Way

Oxford

United Kingdom

OX3 9DU

+44 (0)1865 227226

White9@ndorms.ox.ac.uk

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number**ClinicalTrials.gov number**

Nil known

Secondary identifying numbers

CPMS 42503

Study information

Scientific Title

The World Hip Trauma Evaluation Nine (WHiTE 9) BeST: A multi-centre randomised controlled trial comparing intraoperative cell salvage with standard care in the treatment of hip fractures

Acronym

WHiTE 9

Study objectives

The aim of the main study is to determine the clinical and cost-effectiveness of intraoperative cell salvage, compared to standard care, in improving health-related quality-of-life in patients undergoing hip fracture surgery.

Ethics approval required

Old ethics approval format

Ethics approval(s)

1. Approved 14/08/2019, Wales Research Ethics Committee 5 (Health and Care Research Wales, Castlebridge 4, 15-19 Cowbridge Road East, Cardiff, CF11 9AB; +447970422139; Wales. REC5@wales.nhs.uk), ref: 19/WA/0197
2. Amendment 02 for the main study approved by Wales Research Ethics Committee 5 on 03/04/2020 (details as above)

Study design

Randomised; Interventional; Design type: Treatment, Surgery

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

Health condition(s) or problem(s) studied

Fracture of neck of femur

Interventions

Current interventions as of 08/04/2020:

Patients over 60 years of age, both those with and without capacity, who sustain a hip fracture and are treated operatively, will be potentially eligible to be randomised to either undergo cell salvage or they will follow the standard care pathway- a standard suction system removes blood lost in the operating field and it is disposed of in the clinical waste.

In either treatment arm, patients may receive donor's (allogenic) blood transfusion before the operation. The need for allogenic blood products will be determined on an individual patient basis, following each centre's blood transfusion policy.

Patients who are younger than 60, treated non-operatively or undergoing cannulated hip screw fixation will not be eligible. Patients for whom the treating surgeon has already elected to use cell salvage (for example Jehovah Witness) or those who have sustained a pathological fracture will also be excluded.

Participants will undergo surgery at the next available opportunity on a planned trauma list. Participants will be blinded to the treatment allocation. The operating surgeon cannot be blinded to the allocation but they will not be involved in the assessment of outcomes. Participants will be kept blinded until the completion of the trial when the blinding will be broken if requested by the patients. There will be no formal analysis of the success of the blinding.

Following hip surgery, all patients will undergo a routine rehabilitation prior to discharge from the hospital. Research staff will complete the data regarding the operation received and autotransfusion blood volume will be recorded at baseline. In addition, the following data will be collected:

- Demographic and baseline characteristics (e.g. age, gender, pre-fracture mobility)
- Pre-injury quality of life (EQ5D) and at 4 and 12 months postoperatively
- Routine 'operation notes', perioperative complications, and discharge details
- The volume of blood that was autotransfused, when this was possible
- The number of donor blood units transfused and the date of transfusion will be collected
- Haemoglobin concentration
- Pre and postoperative delirium assessment
- Details of admission, assessment and treatment
- Contact details, including of carers when appropriate
- Complications and SAEs during the study period

Following their 12 months questionnaire, patients will have completed their participation in the trial and will continue to be treated as per normal standard of care.

Previous interventions:

This will be a multi-centre feasibility randomised controlled trial. The study will include a comparison between a cell salvage and autotransfusion with the standard of care approach to the blood lost during hip surgery. The study will be linked to the established WHITE Comprehensive Cohort Study.

Patients over 60 years of age, both those with and without capacity, who sustain a hip fracture and are treated operatively, will be potentially eligible to be randomised to either undergo cell salvage and autotransfusion or they will follow the standard care pathway- a standard suction system removes blood lost in the operating field and it is disposed of in clinical waste. In either treatment arm, patients may receive donor's (allogenic) blood transfusion before the operation. The need for allogenic blood products will be determined on an individual patient basis, following each centre's blood transfusion policy.

Patients who are younger than 60, treated non-operatively or undergoing cannulated hip screw fixation will not be eligible. Patients for whom the treating surgeon has already elected to use cell salvage (for example Jehovah Witness) or those who have sustained a pathological fracture will also be excluded.

Participants will undergo surgery at the next available opportunity on a planned trauma list. Participants will be blinded to the treatment allocation. The operating surgeon cannot be blinded to the allocation but they will not be involved in the assessment of outcomes. Participants will be kept blinded until the completion of the trial when the blinding will be broken if requested by the patients. There will be no formal analysis of the success of the blinding.

Following hip surgery, all patients will undergo a routine rehabilitation prior to discharge from the hospital. Research staff will complete the data regarding the operation received and autotransfusion blood volume will be recorded at baseline. In addition, the following data will be collected:

- Demographic and baseline characteristics (e.g. age, gender, pre-fracture mobility)
- Pre-injury quality of life (EQ5D) and at 30 and 120 days postoperatively
- Routine 'operation notes', perioperative complications, and discharge details
- The volume of blood that was autotransfused, when this was possible
- The number of donor blood units transfused and the date of transfusion will be collected
- Haemoglobin concentration
- Pre and postoperative delirium assessment
- Details of admission, assessment and treatment
- Contact details, including of carers when appropriate
- Complications and SAEs during the study period

Following their 120-day questionnaire, patients will have completed their participation in the trial and will continue to be treated as per normal standard of care.

Intervention Type

Procedure/Surgery

Primary outcome measure

Current primary outcome measure as of 08/04/2020:

Health-related quality of life measured using the EuroQol 5 dimension(EQ-5D-5L) score at baseline (retrospective pre-fracture status) and 4 months post-operatively

Previous primary outcome measure:

1. Recruitment rate per centre
2. The number of patients for whom autotransfusion is possible
3. The volume of blood autotransfused

Secondary outcome measures

Current secondary outcome measures as of 08/04/2020:

1. Health-related quality of life measured using the EuroQol 5 dimension(EQ-5D-5L) score at baseline and 12 months post-operatively
2. Post-operative delirium risk measured using 4AT at baseline
3. Residential status measured using NHFD questions at 4 and 12 months post-surgery
4. Mobility measured using NHFD questions at 4 and 12 months post-surgery
5. Allogenic blood usage measured using hospital records at baseline
6. Mortality measured using death notifications from hospital records at 4 and 12 months post-operatively
7. Haemoglobin concentration at baseline
8. Complications, measured using medical records (check any complication classified as adverse events on the protocol will be collected from recruitment until the 12 -month time point)
9. Costs and comparative cost-effectiveness measured using hospital records and resource use questionnaire at 4 and 12 months post-operatively

Previous secondary outcome measures:

1. Health-related Quality of life will be collected using the EuroQol 5 dimension(EQ-5D-5L) score. This will be collected at baseline(retrospective pre-fracture status), 30 and 120 days post-operatively.
2. Units of allogenic blood transfused, this information will be collected at baseline.
3. Mortality
4. Haemoglobin concentration, this information will be collected at baseline
5. Complications, any complication classified as adverse events on the protocol will be collected from recruitment until the 4-month time point.
5. Resource use, costs and comparative cost-effectiveness

Overall study start date

01/04/2019

Completion date

31/03/2023

Eligibility

Key inclusion criteria

Participants of 60 years of age and older who have sustained a fracture of the hip who, in the opinion of the operating surgeon, would benefit from surgery

Participant type(s)

Patient

Age group

Senior

Sex

Both

Target number of participants

Planned Sample Size: 1,128; UK Sample Size: 1,128

Key exclusion criteria

1. Patients younger than 60 years of age
2. Patients undergoing percutaneous hip screw fixation
3. Patients who have sustained a pathological fracture
4. Patients for whom the treating surgeon has already elected to use cell salvage (for example Jehovah Witness)

Date of first enrolment

01/10/2019

Date of final enrolment

30/11/2021

Locations

Countries of recruitment

England

United Kingdom

Wales

Study participating centre

University Hospital Coventry

University Hospitals Coventry & Warwickshire NHS Trust

Clifford Bridge Road

Coventry

United Kingdom

CV2 2DX

Study participating centre

John Radcliffe Hospital

Headley Way

Oxford

United Kingdom

OX3 9DU

Study participating centre
Royal Berkshire NHS Foundation Trust
Royal Berkshire Hospital
London Road
Reading
United Kingdom
RG15AN

Study participating centre
Medway Maritime Hospital
Medway NHS Foundation Trust
Windmill Road
Gillingham
United Kingdom
ME7 5NY

Study participating centre
St George's Hospital
Blackshaw Road
London
United Kingdom
SW17 0QT

Study participating centre
Royal Derby Hospital
University Hospitals of Derby and Burton NHS Foundation Trust
Uttoxeter Road
Derby
United Kingdom
DE22 3NE

Study participating centre
Queen's Medical Centre
Nottingham University Hospitals NHS Trust
Derby Road
Nottingham
United Kingdom
NG7 2UH

Study participating centre

Whipps Cross Hospital

Leytonstone

London

United Kingdom

E11 1NR

Study participating centre**North Tyneside General Hospital City**

Northumbria Healthcare NHS Foundation Trust

North Shields

United Kingdom

NE29 8NH

Study participating centre**Pinderfields Hospital**

Aberford Road

Wakefield

United Kingdom

WF1 4DG

Study participating centre**University Hospital of Wales**

Heath Park

Cardiff

United Kingdom

CF14 4XW

Study participating centre**Southmead Hospital**

Southmead Road

Bristol

United Kingdom

BS10 5NB

Study participating centre**Doncaster Royal Infirmary**

Armthorpe Road

Doncaster

United Kingdom

DN2 5LT

Study participating centre**Royal Derby Hospital**

Uttoxeter Road
Derby
United Kingdom
DE22 3NE

Study participating centre**University Hospital Of North Durham**

North Road
Durham County
Durham
United Kingdom
DH1 5TW

Study participating centre**The Grange University Hospital**

Caerleon Road
Llanfrechfa
Cwmbran
United Kingdom
NP44 8YN

Sponsor information

Organisation

University Hospitals Coventry and Warwickshire NHS Trust

Sponsor details

Walsgrave General Hospital
Clifford Bridge Road
Coventry
England
United Kingdom
CV2 2DX
+44 (0)2476 965031
R&DSponsorship@uhcw.nhs.uk

Sponsor type

Hospital/treatment centre

ROR

Funder(s)

Funder type

Government

Funder Name

NIHR Central Commissioning Facility (CCF); Grant Codes: PB-PG-0817-20037

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal

Intention to publish date

31/03/2023

Individual participant data (IPD) sharing plan

Reasonable requests for access to the datasets can be made to Prof Xavier Griffin (X.griffin@qmul.ac.uk), three years after the publication of the clinical results of the study.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article		08/06/2022	09/06/2022	Yes	No
HRA research summary			28/06/2023	No	No